Compare · AVTR vs SEER
AVTR vs SEER
Side-by-side comparison of Avantor Inc. (AVTR) and Seer Inc. (SEER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and SEER operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $7.56B, about 63.3x SEER ($119.3M).
- Over the past year, AVTR is down 16.8% and SEER is up 2.8% - SEER leads by 19.6 points.
- SEER has been more active in the news (25 items in the past 4 weeks vs 5 for AVTR).
- AVTR has more recent analyst coverage (25 ratings vs 8 for SEER).
- Company
- Avantor Inc.
- Seer Inc.
- Price
- $11.06-1.78%
- $2.17+0.46%
- Market cap
- $7.56B
- $119.3M
- 1M return
- +15.45%
- +26.53%
- 1Y return
- -16.78%
- +2.84%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 5
- 25
- Recent ratings
- 25
- 8
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Seer Inc.
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Latest AVTR
- Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
- Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
- Bernstein resumed coverage on Avantor with a new price target
- President, VWR Dist. & Servs. Walker Corey covered exercise/tax liability with 3,010 shares, decreasing direct ownership by 0.78% to 384,535 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest SEER
- SEC Form DFAN14A filed by Seer Inc.
- Radoff-JEC Group Announces ISS’ Support of its Case for Change at Seer, Inc.
- SEC Form DEFA14A filed by Seer Inc.
- SEC Form DEFA14A filed by Seer Inc.
- Seer Board of Directors Issues Letter to Shareholders Setting the Record Straight
- Director Nishar Dipchand sold $23,265 worth of shares (10,660 units at $2.18) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 59,044 units (SEC Form 4) to cover withholding tax
- SEC Form DFAN14A filed by Seer Inc.
- The Radoff-JEC Group Issues Letter to Fellow Seer, Inc. Stockholders Correcting the Company’s Blatant Rewriting of History
- SEC Form 144 filed by Seer Inc.
- SEC Form DEFA14A filed by Seer Inc.